BNTX:NASDAQ
BioNTech SE - ADR
97,64Â US$
arrow_upward
+0,76%(+0,74) 1D
98,00Â US$
arrow_upward
+0,37% (+0,36)bedtimeJashtë orarit
Mbyllur: 5 tet, 4:00:01 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për BNTX...
Hap
96,74Â US$
I lartë
98,78Â US$
I ulët
95,20Â US$
Kapitalizimi i tregut
24,53Â mld
Vëllimi mesatar
1,10Â mln
Vëllimi
1,44Â mln
Maksimumi 52-javor
123,98Â US$
Minimumi 52-javor
79,52Â US$
Fitimet për aksion
-7,55Â US$
Beta
1,22
Aksionet në qarkullim
251,20Â mln
Numri i punonjësve
8 mijë
Hap
96,74Â US$
I lartë
98,78Â US$
I ulët
95,20Â US$
Kapitalizimi i tregut
24,53Â mld
Vëllimi mesatar
1,10Â mln
Vëllimi
1,44Â mln
Maksimumi 52-javor
123,98Â US$
Minimumi 52-javor
79,52Â US$
Fitimet për aksion
-7,55Â US$
Beta
1,22
Aksionet në qarkullim
251,20Â mln
Numri i punonjësve
8 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Yahoo Finance
·
2 orë më parë
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
AD HOC NEWS
·
4 orë më parë
BioNTech stock draws Moderate Buy consensus at USD 126 target
AD HOC NEWS
·
9 orë më parë
BioNTech CEO Offloads 100,000 Shares as Founders' Exit Talks Turn Testy
AD HOC NEWS
·
13 orë më parë
Berenberg raises target for BioNTech stock from USD 132 to USD 140
Profili
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Rreth BioNTech SE - ADR